Production (Stage)
Spero Therapeutics, Inc.
SPRO
$2.13
-$0.22-9.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -398.09% | -400.65% | 317.66% | 273.10% | 187.16% |
| Total Depreciation and Amortization | -99.21% | -99.46% | -91.27% | -75.62% | -67.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -40.42% | -37.81% | -36.01% | 42.25% | 17.15% |
| Change in Net Operating Assets | 153.89% | 151.56% | -295.06% | -503.09% | -339.56% |
| Cash from Operations | -135.03% | 28.95% | -160.51% | -218.80% | -285.94% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -99.99% | -98.91% | -98.95% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -99.99% | -98.91% | 100.66% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -138.75% | 28.47% | -140.42% | -143.86% | -157.92% |